Search the Newsreel

Anheuser-Busch InBev SA/NV Q2 Earnings Call Highlights

AB InBev Misses Q2 Earnings & Revenues Estimates, Reaffirms 2026 View

Anheuser-Busch InBev SA/NV BUD, aka AB InBev, reported second-quarter 2026 results, wherein earnings per share and revenues missed the Zacks Consensus Estimate. Both top and bottom lines were flat year over year. BUD reported second-quarter 2026 underlying earnings of 98 cents per share, flat …

This Historic 6-Gigawatt SMR Program Could Be a Game Changer for NuScale Stock

For over three years, NuScale Power (NYSE: SMR) has enjoyed the first-mover advantage of having a small modular reactor (SMR) with Nuclear Regulatory Commission (NRC) certification. What's been missing from NuScale's story, however, is a customer committed to deploying commercial reactors. For NuScale investors, …

19OH Bond Profile — Key Metrics

This article provides key metrics for the Anheuser-Busch InBev NV/SA 3.25% bond, identified by the symbol 19OH on the London Stock Exchange. It details the bond's issue and maturity dates, outstanding amount, face value, minimum denomination, and coupon rate. Additionally, it offers a brief …

Prediction: Buying NuScale Right Now Could Make You Richer by 2036

Key Points AI, data centers, EVs, and electrification could create a substantial market for NuScale's reactors. NuScale has two potential projects, and the completion of either one could help validate its technology. Once NuScale has deployed an SMR commercially, it could inspire confidence and …

Anheuser-Busch InBev stock trades near new 52-week high after Q2 2026 earnings beat

Oklo vs. NuScale vs. Bloom Energy: Which AI-Power Stock Is the Better Buy Now?

To feed the never-ending hunger of artificial intelligence (AI) data centers, big tech companies are seeking alternative solutions beyond relying on traditional power grids. Bloom Energy (NYSE: BE) offers a solution, with its solid oxide technology that provides on-site power. Other sources of power …

Anheuser Busch InBev SA/NV (0RJI) Receives a Buy from RBC Capital

RBC Capital analyst James Edwardes Jones maintained a Buy rating on Anheuser Busch InBev SA/NV with a price target of €85.00. This follows a similar Buy rating from Bernstein's Trevor Stirling, while Barclays recently downgraded the stock to a Hold. The company has a …

BHC Stock Soars As Earnings Beat Fuels Fresh Uptrend

Bausch Health Companies Inc. (BHC) saw its stock jump by 11.53% due to strong Q2 2026 earnings, beating analyst expectations for both EPS and revenue. This marks the 13th consecutive quarter of revenue and adjusted EBITDA growth for the company, signaling a significant turnaround …

Bausch Health Companies Inc. 2026: Revenue $2.85B, EPS $0.68— 10-Q Summary

Bausch Health Companies Inc. reported strong Q2 2026 results with revenue of $2.85 billion, an increase from $2.53 billion year-over-year. Diluted EPS rose to $0.68 from $0.40, and net income attributable to the company significantly increased to $258 million. This growth was driven by …

Bausch + Lomb (BLCO) Lifts 2026 Revenue Guidance, Is The Stock Still 57% Undervalued?

Bausch Health (BHC) Rockets 28% as Q2 Turnaround Fuels Recovery Outlook

Canadian Stock Movers for Friday | Bausch Health Companies Inc Was the Top Gainer; Manufacturing - Apparel & Accessories Led Gains

Truscott Mining Strengthens Corporate Affairs Leadership as Westminster Development Advances

Anheuser-Busch InBev SA/NV (NYSE:BUD) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

AB InBev signals 4% to 8% 2026 EBITDA growth as BEES marketplace scales

Earnings Call Insights: Anheuser-Busch InBev (BUD) Q2 2026 MANAGEMENT VIEW * "The momentum of our business continued in the second quarter" and "Beer volumes increased by 1.1% with market share growth globally" (Chief Executive Officer Michel Doukeris). * "Revenue increased by 5.6%" and "Underlying …

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

(RTTNews) - Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept …

Oklo vs. NuScale: Which One Actually Has Paying Customers Lined Up?

Oklo (NYSE: OKLO) and NuScale Power (NYSE: SMR) remain two of the most popular nuclear energy stocks. However, there's a good reason why excitement about both companies has waned in the past year. Neither company has made much progress exiting the pre-revenue stage. Oklo …

Bausch Health (NYSE: BHC) posts $1.17B H1 loss after $1.43B goodwill hit

Bausch Health (NYSE: BHC) reported a net loss of $1.17 billion for the first half of 2026, primarily due to a $1.43 billion goodwill impairment in its Salix reporting unit. This impairment followed failed Phase 3 clinical trials for a rifaximin formulation. Despite the …

BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised

Bausch Health Companies Inc. BHC reported second-quarter 2026 adjusted earnings of $1.26 per share, up 40% year over year. The figure beat the Zacks Consensus Estimate of 96 cents. Revenues increased 13% year over year to $2.85 billion and surpassed the Zacks Consensus Estimate …

Bausch Health stock gains after Q2 2026 beat (BHC:NYSE)

Bausch Health (BHC) reported better-than-expected Q2 financials and raised its full-year outlook, leading to a significant stock gain of over 27% on Thursday. This performance marks one of the company's best intraday rallies in nearly a decade. The Canadian drugmaker announced $2.9 billion in …

Anheuser-Busch InBev SA/NV (BUD) Releases Q2 2026 Earnings: Revenue Rises 11% and EPS Jumps 183%

Anheuser-Busch InBev SA/NV (BUD) reported robust second-quarter 2026 earnings, with revenue increasing 11% to $16.7 billion and diluted earnings per share jumping 183.5% to $2.38. The company also saw significant growth in net income and operating cash flow, alongside notable hedge fund activity and …

AB InBev Earnings Beat. Why the Bud Light Brewer’s Stock Is Falling.

Beer sales volumes are up 1.1% from a year ago, as events like the FIFA World Cup boost sales of Michelob Ultra and other beers. Continue Reading

Compared to Estimates, Anheuser-Busch Inbev (BUD) Q2 Earnings: A Look at Key Metrics

Anheuser-Busch Inbev (BUD) reported $16.66 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 11%. EPS of $1.21 for the same period compares to $0.98 a year ago. The reported revenue represents a surprise of +2.26% over the Zacks …

ANHEUSER-BUSCH INBEV SA/NV – AB InBev Reports Second Quarter and Half Year 2026 Results – Short Form Announcement

Figure 14. Terms and debt repayment schedule as of 30 June 2026 (billion USD) Solid top- and bottom-line performance: Revenue up by 5.6%, Beer volume growth of 1.1% and a 23.4% Underlying EPS increase BRUSSELS, July 30, 2026--(BUSINESS WIRE)--Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): …

2 Reasons AB InBev Stock Is Dropping After Bud Light Brewer’s Earnings Beat

Beer sales volumes are up 1.1% from a year ago, as events like the FIFA World Cup boost sales of Michelob Ultra and other beers. Continue Reading

Canadian Stock Movers for Thursday | Bausch Health Companies Inc Was the Top Gainer; Capital Markets Led Gains

Bausch Health Companies Inc. (BHC.TO) was Thursday's top gainer in Canadian stock markets, rising 12.18% to close at C$7.32. The Capital Markets sector broadly led Thursday's gains, increasing by 2.22%. Trading volume was robust, with 364.57 million shares changing hands, exceeding the 10-day average.

Earnings To Watch: Anheuser-Busch InBev SA/NV (XBRU:ABI) Q2 2026 -- GF Value Sees 16% Downside

Anheuser-Busch InBev SA/NV (XBRU:ABI) is scheduled to release its Q2 2026 earnings on July 30, 2026, with an expected revenue of $14.35 billion and earnings of $1.18 per share. Analyst estimates suggest a full-year 2026 revenue of $56.45 billion and earnings of $4.10 per …

Anheuser-Busch Inbev Q2 Profit Surges, Sees FY26 EBITDA Growth In Line With Mid-term View

(RTTNews) - Belgian drink and brewing major Anheuser-Busch InBev SA/NV (BUD, ABI.BR) on Thursday reported significantly higher profit in its second quarter, mainly as revenues were benefited by higher beer volume. Looking ahead for fiscal 2026, the company expects EBITDA to grow in line …

Bausch Health Companies Inc (BHC) - Tradingkey

This article provides a comprehensive stock analysis of Bausch Health Companies Inc (BHC) by Tradingkey. It highlights the company's stable fundamentals, high growth potential, and current "Hold" rating from analysts with an upside space targeting 7.17. Despite high institutional ownership and a recent shift …

Anheuser-Busch InBev SA/NV 2026 Q2 - Results - Earnings Call Presentation (NYSE:BUD) 2026-07-30

Anheuser-Busch InBev SA/NV reported higher Q2 revenue, earnings, and free cash flow, driven by increased beer volumes and market share gains globally, although performance in China remained challenging. The company saw strong growth in mega brands, non-alcohol beer, and its "Beyond Beer" portfolio, with …

Anheuser-Busch InBev SA/NV (NYSE:BUD) Reaches New 1-Year High After Strong Earnings

Bausch + Lomb (BLCO) Stock Rallies On Margin Gains As Losses Narrow

AB InBev’s no-alcohol beer revenue rises 27% as beer volume grows

AB InBev reported solid second quarter 2026 results with revenue up 5.6% and underlying EPS increasing by 23.4%, driven by strong beer volume growth and strategic investments. The company saw significant growth in its no-alcohol beer portfolio, with revenue up 27%, and its megabrands …

Anheuser-Busch Inbev: Q2 Earnings Snapshot

AB InBev Reports Second Quarter 2026 Results

Figure 14. Terms and debt repayment schedule as of 30 June 2026 (billion USD) Solid top- and bottom-line performance: Revenue up by 5.6%, Beer volume growth of 1.1% and a 23.4% Underlying EPS increase BRUSSELS, July 30, 2026--(BUSINESS WIRE)--Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): …